
Regeneron Pharmaceuticals statistics
$955.47+0.45%Close 13 Nov 2026
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
| Enterprise value | $94.68B |
|---|
| EV / EBITDA | 17.61 |
|---|
| EV / sales | 5.60 |
|---|
Share price
| Latest close | $955.47 |
|---|
| Day's change | +0.4% |
|---|
| 52-week high | $991.73 |
|---|
| 52-week low | $591.52 |
|---|
| From 52-week high | −3.7% |
|---|
| Return · 1 month | +20.8% |
|---|
| Return · 3 months | +15.6% |
|---|
| Return · year to date | +23.8% |
|---|
| Return · 1 year | +40.2% |
|---|
| Beta · 1 year against the S&P 500 | 0.34 |
|---|
| 50-day average | $816.17 |
|---|
| 200-day average | $746.90 |
|---|
| RSI 14 | 68.4 |
|---|
| Average volume · 20 sessions | 1.0M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Operating margin | 24.9% |
|---|
| Net margin | 31.4% |
|---|
| Free cash flow margin | 28.4% |
|---|
| Return on equity | 14.9% |
|---|
| Return on assets | 7.9% |
|---|
| Return on invested capital | 11.5% |
|---|
| Return on capital employed | 10.2% |
|---|
| Stock-based compensation / revenue | 6.9% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $3.12B |
|---|
| Total debt | $2.25B |
|---|
| Net debt | −$6.35B |
|---|
| Current ratio | 4.13 |
|---|
| Debt / equity | 0.07 |
|---|
| Net debt / EBITDA | −1.54 |
|---|
| Interest coverage | 81.69 |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 109M |
|---|
| Net share repurchases | $2.80B |
|---|
| Dividend payout | 8.2% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $725.8M |
|---|
| Effective tax rate | 13.9% |
|---|
REGN in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.